Results 141 to 150 of about 85,930 (259)

LPC18:0 Secreted by Exogenous Neural Stem Cells Potentiates Neurogenesis and Functional Recovery via GPR55‐Mediated Signalling in Spinal Cord Injury

Cell Proliferation, EarlyView.
LPC18:0 secreted by exogenous neural stem cells potentiates neurogenesis via the GPR55/AKT/GSK3β signalling axis, which ultimately promotes spinal cord injury recovery. ABSTRACT Spinal cord injury (SCI) is a devastating condition with limited therapeutic options. Although neural stem cell (NSC) transplantation shows regenerative potential, its efficacy
Dong Chen, Shuo Liu, Le‐Yi Tu, Ming‐Mei Yang, Cong‐Wang Xu, Yue Jiang, Hui Yang, Chen‐Xu Tai, Yan‐Ning Wang, Yuan‐Yuan Xie, Ping‐Ping Shen, Bin Wang   +11 more
wiley   +1 more source

In Vivo Models of Diabetes: Unravelling Molecular Pathways in Metabolic and Skeletal Complications. [PDF]

Biomedicines
Ahmad Hairi H, Mustafa NH, Shuid AN, Sadikan MZ.   +3 more
europepmc   +1 more source

Application Strategies of Bone Marrow Mesenchymal Stromal Cells in Bone‐Related Diseases

Cell Proliferation, EarlyView.
Engineered BMSCs and vesicles enhance therapy effects for bone diseases via multi‐strategic approaches. ABSTRACT Bone‐related diseases (e.g., osteoporosis, osteoarthritis and fractures) exhibit a rising global incidence, imposing significant burdens on both quality of life and healthcare systems.
Xuemei Long, Dan Tan, Qianke Tao, Qiaonan Ye, Luwen Ye, Qing Li, Jingang Xiao   +6 more
wiley   +1 more source

Molecular, Systemic, and Physiological Adaptations to High-Intensity Interval Training in Flatwater Kayak Athletes. [PDF]

Sports (Basel)
Papandreou A, Tzanis G, Moustogiannis A, Zevolis E, Zacharogiannis E, Maridaki M, Nanas S, Koutsilieris M, Philippou A.   +8 more
europepmc   +1 more source

Beyond diabetes and obesity: GLP‐1 receptor agonists in disrupting the vicious cycle of metabolic dysfunction and neuroinflammation

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Neurodegenerative diseases, including debilitating conditions like Alzheimer's and Parkinson's, are characterized by progressive neuronal loss, a process fundamentally driven by persistent chronic neuroinflammation and central metabolic dysfunction.
Renata Spezani, Carlos A. Mandarim‐de‐Lacerda   +1 more
wiley   +1 more source

Insulin Growth Factor Binding Protein-6 and the Liver. [PDF]

Cells
Coda ARD, Kasperczyk S, Dobrakowski M, Kasperczyk A, Trecca MI, Liso A, Serviddio G, Bellanti F.   +7 more
europepmc   +1 more source

Interactive online calculator for estimation of muscle and hepatic insulin sensitivity in adults with Type 1 diabetes using clinical and research biomarkers

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Impaired insulin sensitivity is an under‐recognised risk in Type 1 diabetes but is challenging to measure with ‘gold‐standard’ euglycaemic clamps. Adding stable‐isotope glucose distinguishes hepatic and muscle insulin action (assessed by endogenous glucose production [EGP] and glucose infusion rate [GIR], respectively).
Andrzej S. Januszewski, Jennifer R. Snaith, Greg M. Kowalski, Clinton R. Bruce, D. Jane Holmes‐Walker, Alicia J. Jenkins, Jerry R. Greenfield   +6 more
wiley   +1 more source

Synaptic Plasticity in Neurodegenerative Diseases: Impact of Exercise as Promising Therapeutic Tool. [PDF]

Cells
Farina G, Fenili G, Paronetto MP, Crescioli C.   +3 more
europepmc   +1 more source

Daily intermittent fasting is an effective multiscale treatment in preclinical models of absence epilepsy

Epilepsia, EarlyView.
Abstract Objective Absence epilepsy is characterized by brief but frequent seizures with loss of consciousness. Existing treatments, which come with heavy side effects, are only partially effective and do not address the associated comorbidities, including cognitive and social deficits.
Coline Rulhe, Steeve Thirard, Juri Aparicio Arias, Leila Makrini, Florence Fauvelle, Emmanuelle Beyne, Alexandra Dauvé, Tristan Bouschet, Emmanuel Valjent, Federica Bertaso   +9 more
wiley   +1 more source

Preclinical pharmacology, pharmacokinetics, and pharmacodynamics of veligrotug, a full antagonist antibody to the IGF-1 receptor in development for thyroid eye disease. [PDF]

MAbs
Kaplan R, Zhao Y, Tsai J, Dickinson B, Swanson T, Foster K, Bedian V.   +6 more
europepmc   +1 more source